EU Approves Daiichi Sankyo And AstraZeneca's Datroway For First-Line Metastatic TNBC, Showing 5.0 Month Overall Survival Improvement Over Chemotherapy In TROPION-Breast02 Trial
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall
A new medicine called Datroway got approved in Europe to treat a tough kind of cancer. It helps patients live about 5 months longer than the old treatment, which is a real win for the companies that made it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.